BeiGene Valuation
Is B1GN34 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of B1GN34 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: B1GN34 (R$45.36) is trading below our estimate of fair value (R$85.55)
Significantly Below Fair Value: B1GN34 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for B1GN34?
Key metric: As B1GN34 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is B1GN34's PS Ratio? | |
|---|---|
| PS Ratio | 6.2x |
| Sales | CN¥23.51b |
| Market Cap | CN¥145.38b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 5.7x |
| Enterprise Value/EBITDA | -23.9x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does B1GN34's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 8.2x | ||
BLAU3 Blau Farmacêutica | 1.6x | 11.2% | R$2.7b |
BIOM3 Biomm | 9.5x | n/a | R$1.2b |
ALNY Alnylam Pharmaceuticals | 14.5x | 22.4% | US$33.3b |
HZNP Horizon Therapeutics | 7.3x | 8.3% | US$26.6b |
B1GN34 BeiGene | 6.2x | 19.3% | R$20.1b |
Price-To-Sales vs Peers: B1GN34 is good value based on its Price-To-Sales Ratio (6.2x) compared to the peer average (8.5x).
Price to Sales Ratio vs Industry
How does B1GN34's PS Ratio compare vs other companies in the Global Biotechs Industry?
| 284 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 284 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: B1GN34 is good value based on its Price-To-Sales Ratio (6.2x) compared to the Global Biotechs industry average (9.2x).
Price to Sales Ratio vs Fair Ratio
What is B1GN34's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 6.2x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate B1GN34's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Novartis
CHF 183.4b
Engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally.
N1VS34
CHF 60.42
7D
-6.4%
1Y
29.5%
Perrigo
US$3.7b
Provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally.
P1RG34
US$148.27
7D
0%
1Y
-0.9%
Biogen
US$23.3b
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.
BIIB34
US$167.50
7D
0.2%
1Y
-8.5%